MX383989B - Sal agonista del receptor opioide, su forma de cristal i de sal de fumarato y método de preparación de la misma. - Google Patents

Sal agonista del receptor opioide, su forma de cristal i de sal de fumarato y método de preparación de la misma.

Info

Publication number
MX383989B
MX383989B MX2019012251A MX2019012251A MX383989B MX 383989 B MX383989 B MX 383989B MX 2019012251 A MX2019012251 A MX 2019012251A MX 2019012251 A MX2019012251 A MX 2019012251A MX 383989 B MX383989 B MX 383989B
Authority
MX
Mexico
Prior art keywords
salt
preparation
crystal form
opioid receptor
mor
Prior art date
Application number
MX2019012251A
Other languages
English (en)
Other versions
MX2019012251A (es
Inventor
Likun Wang
Lin Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019012251A publication Critical patent/MX2019012251A/es
Publication of MX383989B publication Critical patent/MX383989B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se relaciona con un agonista del receptor opioide la sal de fumarato de (1S,4S)-4- etoxi-N-(2-((R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca-9-il)etil)-1,2,3,4-tetrahidronaftalen-1-amina, su forma de cristal I de la sal de fumarato, y un metodo de preparacion y aplicación del mismo.(ver formula)
MX2019012251A 2017-04-14 2018-04-13 Sal agonista del receptor opioide, su forma de cristal i de sal de fumarato y método de preparación de la misma. MX383989B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710242119 2017-04-14
PCT/CN2018/082935 WO2018188643A1 (zh) 2017-04-14 2018-04-13 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法

Publications (2)

Publication Number Publication Date
MX2019012251A MX2019012251A (es) 2019-11-28
MX383989B true MX383989B (es) 2025-03-14

Family

ID=63792318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012251A MX383989B (es) 2017-04-14 2018-04-13 Sal agonista del receptor opioide, su forma de cristal i de sal de fumarato y método de preparación de la misma.

Country Status (23)

Country Link
US (2) US11014914B2 (es)
EP (1) EP3610875B1 (es)
JP (1) JP7153030B6 (es)
KR (1) KR20190140962A (es)
CN (1) CN110049980B (es)
AU (1) AU2018251119B2 (es)
BR (1) BR112019021447A2 (es)
CA (1) CA3057383A1 (es)
CY (1) CY1124063T1 (es)
DK (1) DK3610875T3 (es)
ES (1) ES2828636T3 (es)
HR (1) HRP20210022T1 (es)
HU (1) HUE053244T2 (es)
LT (1) LT3610875T (es)
MX (1) MX383989B (es)
MY (1) MY196571A (es)
PL (1) PL3610875T3 (es)
PT (1) PT3610875T (es)
RS (1) RS61193B1 (es)
SI (1) SI3610875T1 (es)
TW (1) TWI682929B (es)
UA (1) UA124400C2 (es)
WO (1) WO2018188643A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3610875T (lt) * 2017-04-14 2020-11-25 Jiangsu Hengrui Medicine Co., Ltd. Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas
TW201836606A (zh) * 2017-04-14 2018-10-16 大陸商江蘇恆瑞醫藥股份有限公司 一種mor激動劑與kor激動劑聯合在製備緩解和/或治療疼痛的藥物中的用途
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
WO2020073985A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020073984A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
KR20210113824A (ko) 2020-03-09 2021-09-17 건국대학교 산학협력단 뮤 오피오이드 수용체의 활성화제를 유효성분으로 포함하는 기분 장애의 예방용 조성물
EP4361154A4 (en) * 2021-07-13 2025-06-18 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pharmaceutically acceptable salt of a Mor receptor agonist, polymorph thereof, and use thereof
CN117624138A (zh) * 2022-08-29 2024-03-01 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的可药用盐、晶型及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02754B (me) 2011-03-23 2018-01-20 Trevena Inc Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
EP3354649B1 (en) 2015-10-15 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
LT3610875T (lt) * 2017-04-14 2020-11-25 Jiangsu Hengrui Medicine Co., Ltd. Opioido (mor) agonisto druska, jo fumarato druskos i kristalinė forma ir jos gavimo būdas

Also Published As

Publication number Publication date
RU2019136088A3 (es) 2021-06-16
JP7153030B2 (ja) 2022-10-13
DK3610875T3 (da) 2020-12-21
CN110049980A (zh) 2019-07-23
MX2019012251A (es) 2019-11-28
EP3610875A4 (en) 2020-02-19
LT3610875T (lt) 2020-11-25
MY196571A (en) 2023-04-19
TWI682929B (zh) 2020-01-21
RS61193B1 (sr) 2021-01-29
HRP20210022T1 (hr) 2021-03-05
US20210130332A1 (en) 2021-05-06
SI3610875T1 (sl) 2021-02-26
JP2020516642A (ja) 2020-06-11
CA3057383A1 (en) 2018-10-18
KR20190140962A (ko) 2019-12-20
US20200048229A1 (en) 2020-02-13
AU2018251119B2 (en) 2021-07-29
BR112019021447A2 (pt) 2020-05-05
PT3610875T (pt) 2020-11-25
EP3610875A1 (en) 2020-02-19
CN110049980B (zh) 2020-10-20
PL3610875T3 (pl) 2021-04-19
CY1124063T1 (el) 2022-03-24
UA124400C2 (uk) 2021-09-08
RU2019136088A (ru) 2021-05-14
ES2828636T3 (es) 2021-05-27
HUE053244T2 (hu) 2021-06-28
JP7153030B6 (ja) 2023-07-24
TW201837033A (zh) 2018-10-16
US11014914B2 (en) 2021-05-25
AU2018251119A1 (en) 2019-11-07
WO2018188643A1 (zh) 2018-10-18
EP3610875B1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
MY196571A (en) Opioid Receptor (Mor) Agonist Salt, Fumarate Salt I Crystal form Thereof and Preparation Method Thereof
IL280182A (en) Pyridin-2-one compounds useful as SMARCA2 antagonists
IL310699B2 (en) THR-Beta RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF
EP3668682A4 (en) DEVICE AND METHOD FOR FASTENING / RELEASING FASTENING ELEMENTS ARRANGED IN A CIRCLE
AU2018274043A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
EP4349840A3 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
BR112017006232A2 (pt) processos e intermediários na preparação de antagonistas de c5ar
SG11201805586SA (en) Triple glucagon/glp-1/gip receptor agonist
MY200925A (en) Peptide Amide Compound and Preparation Method and Medical use Thereof
EP4235548A3 (en) Method and apparatus for providing calendar displaying work history of document
GB2603330B (en) Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
EP3718557A3 (en) Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
CA2916222C (en) Stable liquid formulation of amg 416 (etelcalcetide)
TN2018000188A1 (en) Isoindole compounds
PH12019501312A1 (en) Spraying device
EA201890981A1 (ru) Новые гетероциклические антиэстрогены
EP3743073A4 (en) COMBINATION TREATMENTS FOR OPIOID CRISIS
EA201691741A1 (ru) Фармацевтическая композиция
EP3147789A4 (en) Method for re-establishing standby database, and apparatus thereof
EP4331674A3 (en) Ghrh antagonists for use in a method of treating sarcoidosis
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
MX2015015746A (es) Proceso para la preparacion de arformoterol o sal del mismo.
NZ710106A (en) A fungicidal composition
EP3461823A4 (en) PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF
TN2014000135A1 (en) Substituted pyrazole analogues as rar antagonists